Sanofi (NASDAQ:SNY) Stake Lessened by Brandywine Global Investment Management LLC

Brandywine Global Investment Management LLC lessened its stake in shares of Sanofi (NASDAQ:SNY) by 0.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 783,816 shares of the company’s stock after selling 2,780 shares during the quarter. Brandywine Global Investment Management LLC’s holdings in Sanofi were worth $37,803,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in SNY. Synergy Asset Management LLC acquired a new stake in Sanofi during the fourth quarter valued at approximately $25,000. McClarren Financial Advisors Inc. grew its holdings in shares of Sanofi by 952.6% in the 4th quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock worth $28,000 after acquiring an additional 543 shares during the last quarter. Lee Danner & Bass Inc. purchased a new position in Sanofi in the 4th quarter worth about $31,000. Sunbelt Securities Inc. increased its stake in Sanofi by 72.1% in the 3rd quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock worth $43,000 after purchasing an additional 313 shares in the last quarter. Finally, Sierra Ocean LLC acquired a new stake in Sanofi during the 4th quarter worth about $44,000. 14.04% of the stock is currently owned by institutional investors and hedge funds.

Sanofi Stock Up 1.7 %

SNY opened at $55.82 on Friday. Sanofi has a twelve month low of $45.22 and a twelve month high of $60.12. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46. The business has a 50 day moving average price of $55.13 and a 200 day moving average price of $52.79. The firm has a market cap of $141.66 billion, a P/E ratio of 22.42, a price-to-earnings-growth ratio of 1.01 and a beta of 0.58.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings data on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. Research analysts forecast that Sanofi will post 4.36 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on SNY. StockNews.com downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. The Goldman Sachs Group assumed coverage on Sanofi in a research report on Friday, March 21st. They issued a “neutral” rating and a $65.00 target price for the company. Finally, Deutsche Bank Aktiengesellschaft raised Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday, January 30th. Three investment analysts have rated the stock with a hold rating, one has assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, Sanofi presently has an average rating of “Moderate Buy” and an average target price of $62.50.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.